Immune Therapeutics is a specialty pharmaceutical company involved in the manufacturing, distribution and marketing of its novel patented therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system. Company’s technology platform is built on two different immunotherapies, Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK).
Type
Public
HQ
Orlando, US
Founded
2012
Size (employees)
10 (est)
Immune Therapeutics was founded in 2012 and is headquartered in Orlando, US
Report incorrect company information

Immune Therapeutics Office Locations

Immune Therapeutics has an office in Orlando
Orlando, US (HQ)
607 37 N Orange Ave
Show all (1)
Report incorrect company information

Immune Therapeutics Financials and Metrics

Immune Therapeutics Financials

Immune Therapeutics's revenue was reported to be $3.46 k in FY, 2016 which is a 78.6% decrease from the previous period.
USD

Net income (Q3, 2017)

(1.6 m)

EBIT (Q3, 2017)

(1.4 m)

Market capitalization (31-Oct-2017)

8.4 m

Closing share price (31-Oct-2017)

0

Cash (30-Sep-2017)

22.6 k
Immune Therapeutics's current market capitalization is $8.4 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

16.2 k3.5 k

Revenue growth, %

(79%)

General and administrative expense

71.1 m4.1 m2.7 m3.9 m

Operating expense total

71.1 m4.1 m2.7 m3.9 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q1, 2017Q3, 2017

Revenue

2.1 k5.6 k5 k3.5 k

Cost of goods sold

Gross profit

General and administrative expense

3.7 m901.7 k402 k443.6 k865.3 k939.3 k666.1 k620.9 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

406.6 k192 k23.1 k74.4 k

Accounts Receivable

16.2 k

Current Assets

622.5 k222 k39.3 k74.4 k

Total Assets

19.2 m6.1 m41.2 k76.4 k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

Cash

58.7 k58.6 k30.9 k22.4 k153.9 k132.8 k64.3 k22.2 k98.1 k22.6 k

Accounts Receivable

2.1 k7.7 k12.7 k19.7 k2.7 k

Inventories

214.3 k

Current Assets

93.7 k108.3 k62.9 k60.1 k211.9 k153.4 k78.2 k22.2 k98.1 k236.9 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(106.1 m)(49.9 m)(16.9 m)(19.8 m)

Depreciation and Amortization

1.2 k2.5 k2.6 k1.6 k

Inventories

246.3 k40 k

Accounts Payable

553.2 k1.8 m900.5 k541 k
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(11.2 m)(2.9 m)(2.6 m)(6.6 m)(2.7 m)

Accounts Payable

1.6 m1.8 m1.9 m1.9 m1.9 m1.9 m1.5 m1.5 m1.7 m
Show all financial metrics
Report incorrect company information